atrasentan

Also known as A-127722, A-147627, ABT-627

Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.

Research

510 papers

Atrasentan in Patients with IgA Nephropathy.The New England journal of medicine · 2025
Atrasentan: First Approval.Drugs · 2025
Atrasentan.2006
Atrasentan.2012
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.Lancet (London, England) · 2019

via PubMed

Wikidata facts

Mass: 510.273

Show 4 more facts

chemical formula: C₂₉H₃₈N₂O₆
isomeric SMILES: CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
canonical SMILES: CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
Commons category: Atrasentan

Sources (2)

via Wikidata · CC0

~2 min read

Article

9 sections

Contents

Medical uses
Society and culture
Legal status
Names
Research
Clinical trials
See also
References
External links

Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.

Atrasentan was approved for medical use in the United States for IgA nephropathy in April 2025.